NCT07368634 2026-01-28
Exploratory Study of EBV-TCR-T Cell Injection for EBV DNAemia After Allogeneic Hematopoietic Stem Cell Transplantation
Chinese PLA General Hospital
Phase 1/2 Recruiting
Clinical Trials
16 trialsNCT02048332 2025-12-16
VSTs
Children's Hospital Medical Center, Cincinnati
Phase 1/2 Recruiting
NCT07133776 2025-08-21
Application of PD-1 Inhibitors Combined With Tenofovir, Chidamide and Lenalidomide in the Treatment of EBV-associated Diseases.
The Affiliated Hospital of Xuzhou Medical University
Phase 1/2 Not yet recruiting
NCT06909110 2025-08-14
Viral Specific T-Lymphocytes to Treat Infection With Adenovirus, Cytomegalovirus or Epstein-Barr Virus in Patients With Compromised Immunity
Stanford University
Phase 1/2 Recruiting
NCT06027879 2025-06-25
Gamma Capture
University of Pittsburgh
Phase 1/2 Enrolling by invitation
NCT02580539 2025-05-14
EBV-TCL-01
Maisonneuve-Rosemont Hospital
Phase 1/2 Completed
NCT03475212 2025-05-11
ACES
Pediatric Transplantation & Cellular Therapy Consortium
Phase 1/2 Active not recruiting
NCT05688241 2025-03-03
ESPECT
University Hospital, Basel, Switzerland
Phase 1/2 Not yet recruiting
NCT03813394 2024-11-22
2018/00947
National University Hospital, Singapore
Phase 1/2 Active not recruiting
NCT06075927 2023-10-10
Multivirus-specific T Cells in the Treatment of Refractory CMV and/or EBV Infection After Allo-HSCT
Peking University People's Hospital
Phase 1/2 Unknown
NCT04507477 2022-08-02
Ex-vivo Delivery of Rituximab to Prevent PTLD in EBV Mismatch Lung Transplant Recipients: A Pilot Trial
University Health Network, Toronto
Phase 1/2 Unknown
NCT00478465 2022-05-27
Valganciclovir (Valcyte) for Chronic Fatigue Syndrome Patients Who Have Elevated Antibody Titers Against Human Herpes Virus 6 (HHV-6)and Epstein-Barr Virus (EBV)
Stanford University
Phase 1/2 Completed
NCT02227641 2020-12-14
Preventative/Preemptive Adoptive Transfer of Peptide Stimulated CMV/EBV Specific T-cells in Patients After Allogeneic Stem Cell Transplantation
University of Erlangen-Nürnberg Medical School
Phase 1/2 Completed
NCT03159364 2019-09-19
Antigen-specific Cytotoxic T Cells in the Treatment of Opportunistic Infections
Shenzhen Geno-Immune Medical Institute
Phase 1/2 Unknown
NCT00711035 2016-04-26
CHALLAH
Baylor College of Medicine
Phase 1/2 Completed
NCT00274404 2011-10-27
Controlled Trial of Valacyclovir in Infectious Mononucleosis
University of Minnesota
Phase 1/2 Completed